HCL-FOUNDATION
16.2.2021 11:37:15 CET | Business Wire | Press release
HCL Foundation, the corporate social responsibility arm of HCL Technologies Ltd., today announced the winners of the sixth round of the HCL Grant, a flagship program dedicated to strengthening India’s “fifth estate” of NGOs working towards nation building.
The three NGOs, one each in the development areas of environment, health, and education, will each receive a grant of INR 5 crore ($685,000) for a three to five-year project. In addition, two finalists in each category will receive a one-year grant of INR 25 lakhs ($34,000), making a total grant of INR 16.5 crore.
HCL Foundation, which this year celebrates a decade of building strong and robust communities, is committed to contributing to the nation’s growth curve. Under its HCL Grant program, the Foundation has so far committed a more than INR 60 crore ($8.26 Million), excluding this year’s grants. Recognized as one of the most sought-after validations amongst NGO ecosystems in India, the HCL Grant has in the past five years reached over 733,000 beneficiaries. The Grant aims to touch the lives of at least 1.72 million people in 8,598 villages in 70 districts across 18 states and two union territories of India.
The winning NGOs of HCL Grant 2021 were:
- Saahas (Environment)
- India Health Action Trust (Health)
- Child Rights and You (Education)
The NGOs were chosen after an 8-month review of thousands of applications by an eminent jury, monitored and audited by Grant Thornton, the governance partner of HCL Grant. The jury consisted of: Ms. Robin Abrams, Director, HCL Technologies, and Chairperson of the jury; Mr. Suresh Narayanan, Chairman and Managing Director, Nestle India Limited; Mr. B. S. Baswan, former Director, Indian Institute of Public Administration, and former Secretary, Human Resource Development ministry; Ms. Pallavi Shroff, Managing Partner, Shardul Amarchand Mangaldas & Co. law firm; Dr. Richard Lariviere, President Emeritus, Field Museum (Chicago), and former President, University of Oregon; and Mr. Shiv Nadar, Founder of HCL, Chief Strategy Officer of HCL Technologies, and Founder and Chairman of the Shiv Nadar Foundation.
“The past year was a unique year of resilience and transformation that taught us how to transcend barriers and keep going even in the face of adversity,” said Ms. Abrams. “Despite the pandemic, the robustness demonstrated by our NGO partners, experts, jury members and the entire team is commendable. The passion and zeal of our NGO partners to bring in scalable and replicable solutions have created systemic shifts across geographies, lending velocity to the sustainable development agenda. The winners and finalists of this year’s Grant also have significant stories to tell, with visible on-the-ground impact. My best wishes to these NGOs, who are addressing some of the most pressing issues in the key development categories of environment, health, and education in the most remote corners of the country.”
Ms. Nidhi Pundhir, Director, HCL Foundation, said: “The year 2020 has been both special and unusual. Special, in that the Foundation is completing ten years of facilitating high-impact, sustainable socio-economic development in rural India. Unusual, in that the NGOs we support had to deal with unprecedented challenges posed by the pandemic and various natural disasters, while initiating and implementing their developmental projects. What is inspiring about these NGOs is that they are treating COVID-19 as the ‘new normal’ and are continuing with their path-breaking projects without a pause, creating a much-needed last-mile support framework.”
On the occasion of the grant awards, the HCL Foundation released “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education,” a compendium featuring the top 30 NGOs selected in the sub-jury round, as well as the previous year’s winning NGOs.
For more information please visit www.hclfoundation.org/hcl-grant
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005593/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
